BioCentury
ARTICLE | Company News

Paion, Cosmo deal

July 18, 2016 7:00 AM UTC

Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. ...